Novo Nordisk Inks Deal with Dewpoint Therapeutics to Boost Diabetes Portfolio

Novo Nordisk and Dewpoint Therapeutics have inked a deal to use the latter’s biomolecular condensates discovery platform to treat insulin resistance and diabetic complications.